FDFT1 and colorectal carcinoma: Moreover, somatic variant analysis indicated that FDFT1 mutation only occurs constantly in the patients with hepatic metastasis, implying that FDFT1-targeted treatment in CRC, particularly in patients with hepatic metastasis, can be a viable strategy (Ma et al., 2019).